多替阿巴拉米片国内上市了吗？

It is an innovative drug for AIDS treatment by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby increasing patients' medication compliance and significantly improving their quality of life. Has Dolutegravir Tablets been launched in China?

In 2015, a clinical application was submitted for dolutea paramilk tablets in China; on January 20, 2017, it applied for import and obtained priority review qualification; on August 1, 2017, the State Food and Drug Administration (CFDA) approved the entry of dolutea paramid tablets, a new compound preparation for AIDS treatment, into China.

Thirty years ago, AIDS was almost equivalent to a terminal illness. Through the joint efforts of doctors and scientists, significant progress has been made in AIDS treatment. Currently, AIDS is becoming a controllable chronic disease. As of June 30, 2016, there were more than 620,000 living HIV/AIDS patients reported across the country, more than 190,000 reported deaths, and more than 420,000 patients currently receiving antiretroviral treatment.

Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of Dolutegra Abalamid Tablets fills this gap and meets the urgent need for convenient medication use by doctors and patients."

Wim Swyzen said that the CFDA has recently taken positive actions in the review and approval of new drugs. GSK will continue to strengthen R&D activities in China and strive to introduce more new AIDS drugs, such as two-in-one compound preparations, long-acting preparations, etc.

It is reported that it has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.